<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603795</url>
  </required_header>
  <id_info>
    <org_study_id>EPAG 2015</org_study_id>
    <nct_id>NCT03603795</nct_id>
  </id_info>
  <brief_title>Study Impact on Outcome of Eltrombopag in Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy</brief_title>
  <acronym>EPAG2015</acronym>
  <official_title>A Phase II Randomized Placebo-controlled Study to Assess the Impact on Outcome of Eltrombopag Administered to Elderly Patients With Acute Myeloid Leukemia Receiving Induction Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II randomized placebo-controlled study to assess the impact on outcome of Eltrombopag&#xD;
      administered to elderly patients with Acute Myeloid Leukemia (AML) receiving induction&#xD;
      chemotherapy. A phase II multicenter and randomized placebo-controlled study&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized 1:1 to receive Eltrombopag or matching placebo, in double&#xD;
      blinded.&#xD;
&#xD;
      To compare overall survival rate at 12 months between the two arms, with or without 200 mg of&#xD;
      Eltrombopag daily after induction chemotherapy&#xD;
&#xD;
      Arm A : Eltrombopag 200 mg (100 mg/day for east Asian heritage) once daily from day 11 of&#xD;
      induction chemotherapy to AML response evaluation or platelets count &gt; 100 x 10 Giga/L&#xD;
      (maximum day 45)&#xD;
&#xD;
      Arm B : Placebo once daily from day 11 of induction chemotherapy to AML response evaluation&#xD;
      or platelets count &gt; 100 x 10 Giga/L. (maximum day 45)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 11, 2018</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomization between 2 arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overal survival rate</measure>
    <time_frame>12 months after beginning treatment</time_frame>
    <description>overall survival rate at month 12 (year 1) between the two arms, with or without 200 mg of Eltrombopag daily after induction chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate (CR and CRi) at day 45</measure>
    <time_frame>At day 45</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leukemia Free Survival at month 12 (one year)</measure>
    <time_frame>12 months after beginning treatment</time_frame>
    <description>relapse measurement before month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term survival</measure>
    <time_frame>2, 3 and 5 years after first treatment administration</time_frame>
    <description>Overall survival at 2, 3 and 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with platelets count &gt; 100 Giga/L at day 45</measure>
    <time_frame>At day 45</time_frame>
    <description>platelets count &gt;100 Giga/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to platelet transfusion independence</measure>
    <time_frame>platelets count daily from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>More than 3 days with platelets count ≥ 10 Giga/L</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of accident haemorrhage events ≥ grade 3</measure>
    <time_frame>Until day 45</time_frame>
    <description>All accident haemorrhage event ≥ grade 3</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of days with platelets count &lt;10 Giga/L</measure>
    <time_frame>from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>Daily measurement of platelets count</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of platelets transfusion</measure>
    <time_frame>from baseline to the end of induction (day 45)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time to platelets count &gt; 100 Giga/L</measure>
    <time_frame>from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>Daily measurement of platelets count</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to peripheral blood polymorphonuclear neutrophils (PMN) counts &gt; 0.5 G/L</measure>
    <time_frame>from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>Daily measurement of peripheral blood PMN count</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to haemoglobin counts &gt; 8 g/dl</measure>
    <time_frame>from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>Daily measurement of haemoglobin count</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to red blood cells transfusion independence</measure>
    <time_frame>from baseline to the end of induction (day 45) and then at day 60, day 90, monthly until year 1 and finally at year 2, year 3 and year 5</time_frame>
    <description>Daily measurement of Red blood cells count and transfusion monitoring</description>
  </other_outcome>
  <other_outcome>
    <measure>Eltrombopag-Emergent Adverse Events</measure>
    <time_frame>Until day 90</time_frame>
    <description>Incidence and severity of Eltrombopag-Emergent Adverse Events utilizing National Cancer Institute - Common Terminology Criteria (NCI-CTC) criteria v4.03</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of quality of life</measure>
    <time_frame>At baseline and at the end of induction (maximum up to day 45)</time_frame>
    <description>EORTC Quality of Life Questionnaire - Core Questionnaire (QLQ-C30). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items.&#xD;
Each of the multi-item scales includes a different set of items - no item occurs in more than one scale.&#xD;
All of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>55 patients will be randomized in the experimental arm A. If platelets counts &lt; 100 x 10 Giga/L, patients will be treated with Eltrombopag 200 mg/day per os from day 11 of induction chemotherapy to platelets counts &gt; 100 x 10 Giga/L or maximum to day 45. If platelets counts ≥ 100 x 10 Giga/L on day 11, the start of IP will be delayed until platelets &lt; 100 x 10 Giga/L.&#xD;
Chemotherapy administration would be performed among standard practice:&#xD;
Daunorubicin: 60 mg/m² D1 to D3&#xD;
Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7&#xD;
Lomustine (CCNU): 200 mg/m² per os, at D1.&#xD;
200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.&#xD;
Investigational Product (IP) will be taken at the same time daily on an empty stomach 1 hour before or 2 hours after a meal or preferably no calcium or dairy products.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>55 patients will be randomized in the comparator arm B and will received: Placebo once daily from day 11 of induction chemotherapy to AML response evaluation or platelets count &gt; 100 x 10 Giga/L (maximum day 45)&#xD;
Placebo 200mg = 4 Tablets of 50 mg will be done more than 2 hours before Daunorubicin and cytarabine administrations, to avoid vomiting secondary to anthracycline administration.&#xD;
Chemotherapy administration would be performed among standard practice:&#xD;
Daunorubicin: 60 mg/m² D1 to D3&#xD;
Cytarabine: 100 mg/m²/day, in a continuous 24h-IV infusion D1 to D7&#xD;
Lomustine (CCNU): 200 mg/m² per os, at D1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>Eltrombopag concomitant with induction chemotherapy in patient with AML</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Arm Eltrombopag</other_name>
    <other_name>Arm experimental A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo concomitant with induction chemotherapy patients with AML</description>
    <arm_group_label>B</arm_group_label>
    <other_name>Arm placebo</other_name>
    <other_name>Arm B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  60 years of age.&#xD;
&#xD;
          -  AML de novo, except AML 3 and AML 7.&#xD;
&#xD;
          -  AML with no adverse cytogenetic according to Medical Research Council (MRC) 2010&#xD;
             classification.&#xD;
&#xD;
          -  Subjects should be eligible for intensive chemotherapy by Daunorubicine, cytarabine,&#xD;
             Lomustine.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) &lt; 3 (appendix 1).&#xD;
&#xD;
          -  SORROR ≤ 3 (appendix 2).&#xD;
&#xD;
          -  Adequate baseline organ function defined by the criteria below:&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN) range except cases clearly&#xD;
                  not indicative of inadequate liver function&#xD;
&#xD;
               -  Alanine Aminotransferase (ALAT) and Aspartate Aminotransferase (ASAT) ≤ 3 x ULN&#xD;
&#xD;
               -  Creatinin ≤ 1.5 x ULN&#xD;
&#xD;
          -  Adequate cardiac function with Left Ventricular Ejection fraction (LVEF) ≥50%&#xD;
&#xD;
          -  Absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule.&#xD;
&#xD;
          -  Women will be menopausal to be enrolled&#xD;
&#xD;
          -  The patient must give written (personally signed and dated) informed consent before&#xD;
             completing any study-related procedure which means assessment or evaluation that would&#xD;
             not form part of the normal medical care of the patient and before the start of&#xD;
             induction chemotherapy.&#xD;
&#xD;
          -  Affiliated to the French Social Security (Health Insurance).&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Subjects with a diagnosis of acute promyelocytic (M3) or megakaryocytic leukemia (M7).&#xD;
&#xD;
          -  AML with adverse cytogenetic according to the MRC 2010 classification.&#xD;
&#xD;
          -  AML secondary to Myelodysplastic syndrome (MDS), Myeloproliferative neoplasm (MPN)&#xD;
&#xD;
          -  Clinical symptoms suggesting active central nervous system leukemia, or presence of&#xD;
             extramedullary AML.&#xD;
&#xD;
          -  Previous exposure to anthracycline.&#xD;
&#xD;
          -  Previous AML treatment other than hydroxyurea.&#xD;
&#xD;
          -  Treatment with an investigational drug within 30 days or 5 half-life whichever is&#xD;
             longer, preceding the first dose of study medication.&#xD;
&#xD;
          -  History of thromboembolic event or other condition requiring ongoing use of&#xD;
             anticoagulation either with warfarin or low molecular-weight heparin.&#xD;
&#xD;
          -  History of another malignancy within the past three years except basal cell carcinoma&#xD;
             of the skin or carcinoma in situ of the cervix.&#xD;
&#xD;
          -  Pre-existing cardiovascular disease (including congestive heart failure, New York&#xD;
             Heart Association (NYHA) Grade III/IV), or arrhythmia known to increase the risk of&#xD;
             thromboembolic events (e.g. atrial fibrillation), or subjects with a QTc &gt;450 msec&#xD;
             (QTc &gt;480 msec for subjects with Bundle Branch Block).&#xD;
&#xD;
          -  Patient requiring platelets transfusion with platelets &gt; 10 x 10 Giga/L, for whatever&#xD;
             reason.&#xD;
&#xD;
          -  History of treatment with romiplostim or other Thrombopoietin receptor (TPO-R)&#xD;
             agonists.&#xD;
&#xD;
          -  Uncontrolled active infection.&#xD;
&#xD;
          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would place the participant at an unacceptable risk or prevent them from giving&#xD;
             informed consent.&#xD;
&#xD;
          -  Known active HIV, Hepatitis B or C infection.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnaud PIGNEUX, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organization (FILO)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU ANGERS - Maladies du sang</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de la Côte Basque - Hématologie</name>
      <address>
        <city>Bayonne</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble - Hématologie Clinique</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli-Calmettes - Hématologie 2</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Eloi - Hématologie Clinique</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOPITAL E. MULLER - Hématologie</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU HOTEL DIEU - Hématologie Clinique</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Caremeau</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU La Milétrie - Hématologie Clinique</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre - Hématologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse Oncopole - Service d'Hématologie</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sponsor FILO</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO internet site</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

